BRPI1002093A2 - Utilização de pelo menos uma forma complexa da proteína da pele de tipo calmodulina e processos de caracterização de um estado de um epitélio e da eficácia de um tratamento e de triagem de ativos anti-idade - Google Patents

Utilização de pelo menos uma forma complexa da proteína da pele de tipo calmodulina e processos de caracterização de um estado de um epitélio e da eficácia de um tratamento e de triagem de ativos anti-idade Download PDF

Info

Publication number
BRPI1002093A2
BRPI1002093A2 BRPI1002093-4A BRPI1002093A BRPI1002093A2 BR PI1002093 A2 BRPI1002093 A2 BR PI1002093A2 BR PI1002093 A BRPI1002093 A BR PI1002093A BR PI1002093 A2 BRPI1002093 A2 BR PI1002093A2
Authority
BR
Brazil
Prior art keywords
calmodulin
treatment
state
assets
characterization
Prior art date
Application number
BRPI1002093-4A
Other languages
English (en)
Inventor
Donovan Mark
Bernard Dominique
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41057464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1002093(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by L'oreal filed Critical L'oreal
Publication of BRPI1002093A2 publication Critical patent/BRPI1002093A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UTILIZAçãO DE PELO MENOS UMA FORMA COMPLEXA DA PROTEìNA DA PELE DE TIPO CALMODULINA E PROCESSOS DE CARACTERIZAçãO DE UM ESTADO DE UM EPITéLIO E DA EFICáCIA DE UM TRATAMENTO E DE TRIAGEM DE ATIVOS ANTI-IDADE. A presente invenção tem por objetivo a utilização de uma forma complexa da proteína "calmodulin-like skin protein" (CLSP), polipeptídeos derivados desta proteína ou análogos dos mesmos, a título de marcador para a avaliação de um estado de um epitélio. A invenção refere-se igualmente à utilização destas formas complexas para triagem de compostos biológicos ou químicos susceptíveis de modular uma atividade biológica das referidas formas complexas e/ou para a preparação e/ou a melhoria de um modelo celular pluriestratificado.
BRPI1002093-4A 2009-01-13 2010-01-12 Utilização de pelo menos uma forma complexa da proteína da pele de tipo calmodulina e processos de caracterização de um estado de um epitélio e da eficácia de um tratamento e de triagem de ativos anti-idade BRPI1002093A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0950162A FR2940977B1 (fr) 2009-01-13 2009-01-13 Utilisation de formes complexes de la proteine de type calmodulin-like skin protein clsp
US20207709P 2009-01-27 2009-01-27

Publications (1)

Publication Number Publication Date
BRPI1002093A2 true BRPI1002093A2 (pt) 2012-03-13

Family

ID=41057464

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1002093-4A BRPI1002093A2 (pt) 2009-01-13 2010-01-12 Utilização de pelo menos uma forma complexa da proteína da pele de tipo calmodulina e processos de caracterização de um estado de um epitélio e da eficácia de um tratamento e de triagem de ativos anti-idade

Country Status (8)

Country Link
US (2) US9453848B2 (pt)
EP (1) EP2209005B1 (pt)
JP (1) JP5980469B2 (pt)
KR (1) KR101231127B1 (pt)
CN (2) CN101806803A (pt)
BR (1) BRPI1002093A2 (pt)
ES (1) ES2669298T3 (pt)
FR (1) FR2940977B1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5945142B2 (ja) * 2012-03-27 2016-07-05 株式会社 資生堂 しわ改善効果について化粧料を評価する方法
CN103575908B (zh) * 2013-10-30 2016-01-13 浙江理工大学 一种古代文物材料中胶原蛋白的检测方法
CN103575907B (zh) * 2013-10-30 2015-12-02 浙江理工大学 一种古代胶结剂文物材料中卵蛋白的检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2667778B1 (fr) 1990-10-16 1995-05-12 Oreal Cellule permettant de collecter sur la peau, par circulation de liquide, au moins un compose a doser.
US20030104362A1 (en) * 1995-06-05 2003-06-05 Guillaume Cottarel Cell-cycle regulatory proteins from human pathogens, and uses related thereto
FR2796646B1 (fr) * 1999-07-23 2003-10-17 Oreal Polypeptide isole du stratum corneum et son utilisation
DE10100121A1 (de) 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
WO2002092765A2 (en) * 2001-05-11 2002-11-21 Beth Israel Deaconess Medical Center Novel telomerase inhibitors and uses therefor
US20030152964A1 (en) * 2001-11-08 2003-08-14 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Methods of identifying photodamage using gene expression
DE60332112D1 (de) * 2002-06-03 2010-05-27 Oreal Topische anwendung mindestens eines doppelsträngigen rna-oligonucleotids (ds rna) gegen tyrosinase
FR2850277B1 (fr) * 2003-01-24 2005-04-08 Lanatech Composition comprenant un extrait d'aphanizomenon flos-aquae, son utilisation et sa preparation
FR2857588B1 (fr) * 2003-07-17 2007-11-30 Oreal Utilisation de beta-endorphine, d'agents exercant une activite beta-endorphine-like en cosmetique et dermatologie
TWI434039B (zh) * 2005-03-18 2014-04-11 Shiseido Co Ltd 以鱗狀細胞癌抗原為指標之皮膚性狀評估方法
FR2924947B1 (fr) 2007-12-18 2010-03-19 Oreal Utilisation cosmetique de proteines de type calmodulin-like skin protein clsp
FR2940976B1 (fr) 2009-01-13 2017-11-03 Oreal Utilisation a des fins de criblage d'actifs anti-ages de formes solubles de la proteine de type desmogleine i

Also Published As

Publication number Publication date
ES2669298T3 (es) 2018-05-24
FR2940977B1 (fr) 2016-11-18
JP2010164563A (ja) 2010-07-29
EP2209005A1 (fr) 2010-07-21
CN106872711A (zh) 2017-06-20
CN101806803A (zh) 2010-08-18
KR20100083739A (ko) 2010-07-22
US20140348816A1 (en) 2014-11-27
FR2940977A1 (fr) 2010-07-16
US20100267642A1 (en) 2010-10-21
EP2209005B1 (fr) 2018-02-28
US9453848B2 (en) 2016-09-27
KR101231127B1 (ko) 2013-02-07
US10060931B2 (en) 2018-08-28
JP5980469B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
PH12015502581A1 (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
BRPI0710485B8 (pt) composições líquidas úteis no tratamento de doenças respiratórias
BRPI0518198A (pt) métodos de interrupção melhorados para processos de inativação de células hemácias
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
ATE481978T1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0512397A (pt) composto,produto farmacêutico, métodos para suprimir a metástase de cáncer ou o crescimento do cáncer, para prevenir ou tratar uma doença ou condição, para controlar a função placentária, para melhorar a função gonadal, para induzir ou estimular a ovulação, para promover a secreção do hormÈnio gonadotrópico ou promover a secreção do hormÈnio sexual, para suprimir a secreção do hormÈnio gonadotrópico ou suprimir a secreção do hormÈnio sexual, para infra regular hormÈnio gonadrotópico ou hormÈnio sexual, e a proteìna ot7t175 humana, e para realçar a estabilidade no sangue, uso do composto, e, agente para suprimir a secreção do hormÈnio gonadotrópico ou um agente para suprimir a secreção do hormÈnio sexual
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
WO2008061208A3 (en) Arylsulfonamide compounds
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
EA201691260A1 (ru) ВАРИАНТЫ, ПРОИСХОДЯЩИЕ ИЗ ActRIIB, И ИХ ПРИМЕНЕНИЕ
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
WO2008018642A3 (en) Genes and polypeptides relating to breast cancers
UY33276A (es) Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso
WO2008127680A3 (en) Diagnosis and treatment of diseases caused by misfolded proteins
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
WO2017105565A3 (en) Compositions for therapeutics, targeted pet imaging and methods of their use
BR112014028654A2 (pt) composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos
BRPI1002093A2 (pt) Utilização de pelo menos uma forma complexa da proteína da pele de tipo calmodulina e processos de caracterização de um estado de um epitélio e da eficácia de um tratamento e de triagem de ativos anti-idade

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL